Clinical trials: Disease, Adnexal
Ovarian Cancer
PROV-MESH: Prophylactic Ovarian Cancer MESH
Incisional hernia is a common complication after midline laparotomy and may significantly impact quality of life, morbidity, and healthcare costs.
- Trial name
- PROV-MESH (NCT07676370)
- Testing
- Prophylactic Mesh Placement, Negative Pressure Wound Therapy (NPWT), Standard Fascial Closure
- Where
- Spain
- Volunteers
- 152 people
- Sponsor
- Hospital Vall d'Hebron
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer
- Trial name
- NCT00003173
- Testing
- filgrastim, thiotepa, autologous bone marrow transplantation
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This was a Phase 1, open-label study of repeated vaccination with NY-ESO-1 overlapping peptides (OLP4) with or without the immunoadjuvants Montanide and polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00616941
- Testing
- NY-ESO-1 OLP4, NY-ESO-1 OLP4 + Montanide, NY-ESO-1 OLP4 + Montanide + Poly-ICLC
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Ludwig Institute for Cancer Research
Ovarian Cancer
A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation
Study population will consist of HRD+ (BRCAm +/- positive genomic instability score according to used test system) OC with available medical history.
- Trial name
- OVARD (NCT05918042)
- Where
- 24 sites in Russia
- Volunteers
- 414 people
- Sponsor
- AstraZeneca
Breast Cancer, Ovarian Cancer
A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT06738966
- Testing
- BL0175
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Fallopian Tube Cancer, Ovarian Cancer
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
This was a Phase 2, single-center, open-label study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) injections in patients who had a complete response to standard therapy for…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00112957
- Testing
- rV-NY-ESO-1 vaccine, rF-NY-ESO-1 vaccine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ludwig Institute for Cancer Research
Ovarian Neoplasms, Sarcopenia
Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer
Prospective monocentric study, non-randomized of the detection of sarcopenia in clinical practice in patients with ovarian or endometrial cancer requiring systemic oncological treatment.
- Trial name
- SARCO-GYN (NCT05833321)
- Testing
- Sarcopenia diagnostic test
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Centre Hospitalier Metropole Savoie
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Carcinoma
- Trial name
- NCT03824704
- Testing
- Rucaparib, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- pharmaand GmbH
Renal Cell Carcinoma, Ovarian Tumor
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC).
- Trial name
- NCT04707248
- Testing
- DS-6000a
- Where
- 13 sites in United States, Japan
- Volunteers
- 179 people
- Sponsor
- Daiichi Sankyo
Ovarian Cancer
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00562185
- Testing
- carboplatin, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Ovarian Neoplasms
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
The purpose of this study is to determine if participants with platinum-refractory or platinum-resistant advanced ovarian cancer have a better outcome when treated with Olaratumab (IMC-3G3) in combination with Liposomal…
- Trial name
- NCT00913835
- Testing
- Olaratumab, liposomal doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Peritoneal Carcinoma, Ovarian Cancer
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2)
Epithelial ovarian carcinoma (EOC) is one of the main cause of death from cancer in women in the Western world. It is often diagnosed at an advanced stage and the disease remains confined to the peritoneal cavity for much of its…
- Trial name
- Cyto-chip 2 (NCT03931304)
- Testing
- Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Hospices Civils de Lyon
Recurrent Ovarian Cancer
Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
Bevacizumab has been found to prolong progression free survival in first line, and more recently, in second line treatment for platinum sensitive ovarian cancer patients who had not received prior treatment with bevacizumab.
- Trial name
- MITO16MANGO2b (NCT01802749)
- Testing
- Bevacizumab, Paclitaxel, Carboplatin
- Where
- 82 sites in France, Greece and 3 more
- Volunteers
- 406 people
- Sponsor
- National Cancer Institute, Naples
Breast Cancer, Ovarian Neoplasm
Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel
Paclitaxel, a widely used chemotherapeutic agent, is associated with several well-known side effects including neuropathy (weakness, numbness and pain) and generalized body aches.
- Conditions
- Breast Cancer, Ovarian Neoplasm, Pain
- Trial name
- NCT01821833
- Testing
- Omega-3 fatty acid, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- New Mexico Cancer Research Alliance
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Cancer (OvCa), Ovarian Cancer Metastatic
O-RADS MRI System on Early Detection of Ovarian Cancer
This study is designed to prospectively enroll individuals with suspected or potential risk of ovarian cancer across multiple centers.
- Trial name
- NCT07009743
- Testing
- MRI contrast-enhancing agents
- Where
- China
- Volunteers
- 2,549 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Ovarian Cancer
Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin
The treatment of advanced ovarian cancer is based on the combination of chemotherapy based on platinum salt and surgery whose quality is the major prognostic factor.
- Trial name
- ISOTOVE (NCT02667925)
- Testing
- Intraperitoneal cisplatin with nanocis
- Where
- France
- Sponsor
- Centre Jean Perrin
Recurrent Ovarian Cancer, HER2-negative
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
- Conditions
- Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC
- Trial name
- HS-10502 (NCT06769425)
- Testing
- HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Ovarian Carcinoma, Fallopian Tube Cancer
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
This is a phase-I clinical trial to determine the feasibility and safety of Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01312376
- Testing
- OC-DC vaccine, Bevacizumab, cyclophosphamide 300 mg/m2/d for 3 days
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.